Basilea Pharmaceutica AG BPMUF
Set alert
77.40 USD +1.15 +1.51%
At close · Oct 30
77.40 Day range 77.40
59.29 52-week range 77.40
- YTD
- +22.37%
- 1 year
- +29.06%
- Open
- 77.40
- Prev close
- 76.25
- Mkt cap
- 959.30M
- Vol
- 100
- Avg vol
- 6
- EPS
- 5.05
- P/E
- 15.33
More statistics
- Low
- 77.40
- High
- 77.40
6M chart
Signals (10)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Sep 4, 2026 | 1 month ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| RSI: Overbought | Aug 3, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 10, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | May 7, 2026 | 5 months ago |
News
- Basilea Pharmaceutica AG (BPMUF) Q2 2026 Earnings Call Transcript
- Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update
- Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
- Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
- Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
- Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
- Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
- Basilea Pharmaceutica AG (BPMUF) Q4 2025 Earnings Call Transcript
- Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
- Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Your note
Sign in to keep a note on BPMUF — it syncs with the Stock Master app.